Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Myeloid Leukemia
67%
Hematopoietic Cell Transplantation
55%
Confidence Interval
45%
Protease Inhibitors
38%
Late Effects
35%
Relapsed or Refractory
35%
Quality of Life
33%
Working Party
33%
Transplant Complications
33%
Routine Imaging
33%
Expert Review
33%
Ocular Complications
33%
Texas Cancer Registry
33%
Classical Hodgkin Lymphoma
33%
Hodgkin Lymphoma
28%
Lymphoma Patients
26%
Myeloma Cells
26%
Myelodysplastic Syndrome
25%
COVID-19
25%
Haploidentical Transplantation
24%
Checkpoint Inhibitors
24%
Radiation Therapy
23%
Older Patients
23%
CIBMTR
23%
Programmed Death-ligand 1 (PD-L1)
23%
LILRB3
22%
Mechanically Ventilated
22%
Tocilizumab
22%
Clinical Outcomes
22%
Mycobacterial Infection
22%
Bloodstream Infection
22%
CAR T-cell Therapy
22%
Increased Mortality
22%
Myeloma
22%
Leukemia Progression
22%
Unrelated Donor
22%
Cytomegalovirus Reactivation
22%
Myeloproliferative Neoplasms
22%
Burkitt Lymphoma
22%
Risk Factors
22%
Overall Survival
21%
Malignancy
20%
Reduced-intensity Conditioning
20%
Haploidentical
20%
Lymphoma
19%
Carfilzomib
17%
Multiple Myeloma
17%
Relapsed Lymphoma
17%
Working Diagnosis
16%
Medicine and Dentistry
Cell Transplantation
83%
Hematopoietic Cell
83%
Acute Myeloid Leukemia
79%
Diseases
42%
Graft Versus Host Reaction
38%
Overall Survival
37%
Myelodysplastic Syndrome
36%
Radiation Therapy
34%
Autologous Stem Cell Transplantation
33%
Late Effect
33%
Quality of Life
33%
Hodgkin's Lymphoma
33%
Cancer Registry
33%
Classical Hodgkin Lymphoma
33%
Cancer
26%
T-Cell Lymphoma
24%
Cytomegalovirus
23%
COVID-19
22%
Burkitt's Lymphoma
22%
Tocilizumab
22%
Reduced Intensity Conditioning
22%
Stem Cell Therapy
22%
CAR T-cell therapy
22%
Receptor
22%
Asparaginase
22%
Conditioning
20%
Melphalan
19%
Systemic Therapy
19%
Leukemia
19%
T Cell
19%
Programmed Cell Death
18%
High Dose Chemotherapy
17%
Leukemia Cell
16%
Etoposide
16%
Peripheral T-Cell Lymphoma
16%
Chimeric Antigen Receptor T-Cell
15%
Hazard Ratio
14%
Nivolumab
14%
Stem Cell Transplant
14%
Brentuximab Vedotin
13%
Retrospective Study
13%
Second Cancer
12%
Leukocyte
12%
Carboplatin
12%
Immune Checkpoint Inhibitor
12%
Metastatic Carcinoma
12%
Rituximab
11%
Chronic Myelogenous Leukemia
11%
Left Ventricular Assist Device
11%
Myeloproliferative Neoplasm
11%